Although immune checkpoint inhibitors are associated with low response rates in CCAs, mutations in PTPN11 in glioblastoma, an immunotherapy refractory cancer, is associated with clinical benefit after treatment with anti-PD-1 antibodies35. Here, PTPN11 is linked to glioblastoma.